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Nuclear receptors are ligand-inducible transcription
factors that share structurally related DNA-binding
(DBD) and ligand-binding (LBD) domains. Biochemical
and structural studies have revealed the modular na-
ture of DBD and LBD. Nevertheless, the domains func-
tion in concert in vivo. While high-resolution crystal
structures of nuclear receptor DBDs and LBDs are avail-
able, there are no x-ray structural studies of nuclear
receptor proteins containing multiple domains. We re-
port the solution structures of the human retinoid X
receptor DBD-LBD (hRXRAB) region. We obtained ab
initio shapes of hRXRAB dimer and tetramer to 3.3
and 1.7 nm resolutions, respectively, and established the
position and orientation of the DBD and LBD by fitting
atomic coordinates of hRXR DBD and LBD. The dimer
is U-shaped with DBDs spaced at 2 nm in a head to
head orientation forming an angle of about 10° with
respect to each other and with an extensive interface
area provided by the LBD. The tetramer is a more elon-
gated X-shaped molecule formed by two dimers in head
to head arrangement in which the DBDs are extended
from the structure and spaced at about 6 nm. The close
proximity of DBDs in dimers may facilitate homodimer
formation on DNA; however, for the homodimer to bind
to a DNA element containing two directly repeated half-
sites, one of the DBDs would need to rotate with respect
to the other element. By contrast, the separation of
DBDs in the tetramers may account for their decreased
ability to recognize DNA.
The nuclear receptor gene family in humans consists of at
least 48 structurally related proteins that regulate transcrip-
tion of target genes (1). These include receptors for the steroid
and thyroid hormones, retinoids, vitamin D, prostaglandins,
fatty acids, and unknown ligands, the orphan receptors. Nu-
clear receptors are comprised of single polypeptide chains that
contain modular domains (2–4). The N termini of the receptors,
which are the most variable in length, have transcription
transactivation functions. The centrally placed and highly con-
served DNA-binding domain (DBD)1 directs receptor binding to
DNA and is also involved in dimerization. The carboxyl-termi-
nal ligand-binding domain (LBD) binds the ligand and under-
goes ligand-induced conformational changes that promote dis-
sociation of corepressors and association of coactivators that
mediate receptor-induced changes in transcriptional control.
The LBD also participates in receptor homodimerization, het-
erodimerization, and oligomerization (5, 6).
Retinoids exert multiple effects on morphogenesis and dif-
ferentiation in fetal and adult organs and regulate glucose and
lipid homeostasis. They also act as potent inhibitors of onco-
genesis in rodent models and are used as chemo-preventive and
therapeutic agents in several types of cancers in humans (7–
12). In mice retinoid X receptor (RXR) selective agonists func-
tion as insulin sensitizers and can decrease hyperglycemia,
hypertriglyceridemia, and hyperinsulinemia (13). The three
RXR isoforms (, , and ) bind to 9-cis retinoic acid and can
function either as homodimers or heterodimers with many
other members of the nuclear receptor family, including the
receptors for thyroid hormones (TRs), vitamin D, and the per-
oxisome proliferator-activated receptors. RXR homodimers
bind preferentially to direct repeats (DRs) of the AGGTCA
half-site spaced by one nucleotide (DR-1), whereas het-
erodimers with peroxisome proliferator-activated receptors, vi-
tamin D receptors, TRs, and retinoic acid receptors bind to DRs
spaced by 1, 3, 4, or 5 nucleotides, respectively.
The RXR has been reported to exist either as a mixed popu-
lation of monomers, dimers, and tetramers (14) or monomers
and tetramers (15) in solution. In the absence of ligand, the
values for Kd monomer3dimer and Kd dimer3tetramer are 130 and
2.8 nM, respectively, as calculated from fluorescence anisotropy
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titration studies, indicating that in this setting tetramer for-
mation is favored (14). Addition of ligand to tetramers in solu-
tion leads to their rapid dissociation to form homodimers (14,
15). Moreover, unliganded RXR dimers bind DR-1 relatively
strongly, but the tetramers do not. Addition of DR-1 DNA to
tetramer-containing solutions leads to formation of dimers.
Thus, both ligand and the RXR cognate DNA element shift the
dynamic equilibrium between RXR tetramer and dimer so that
dimer formation is enhanced.
A large number of isolated nuclear receptor DBD and LBD
structures have been obtained in crystal and in solution. The
RXR DBD has been solved in complexes with DNA as ho-
modimers and as heterodimers with the TR DBD and retinoic
acid receptor DBD (16–18). The RXR homodimer DBD binds to
the DR-1 element as a head to tail dimer. The distance between
the DR-1 half-site sequences is 3 nm, and part of the -helix
connecting DBDs to LBD (T-box) unwinds allowing efficient
DNA binding and DBD dimerization (18). RXR LBDs have been
crystallized in a variety of forms, including dimers and tetra-
mers (19–23). The LBDs are mostly -helical with the ligand
buried in the interior of the holo-receptor and contributing to
formation of the hydrophobic core of the protein. There are
significant structural differences between the RXR LBD apo-
and holo-forms. In particular, transactivation helix (H12) pro-
trudes from the body of the receptor in the absence of ligand,
but packs against the body of receptor in its presence (19, 20,
24, 25). This repositioning of H12 completes formation of a
hydrophobic cleft that also contains residues of H3, 4, and 5
and forms a docking site for LXXLL motifs in nuclear receptor
coactivators. The RXR LBD dimer interface overlaps residues
from the intersection of helices 7, 9, and 10 (21) and corre-
sponds to the position of the TR homo- and heterodimerization
interface as defined by site-directed mutagenesis (26). A crystal
structure of an RXR-LBD tetramer, along with solution x-ray
scattering studies of the same oligomer (21, 22), reveals that it
consists of a head to head “dimer of dimers” with a large (2750
Å2) interface comprised of residues from H3, H11, and H12
(discussed further below). This extensive tetramer interface is
thought to contribute to the marked stability of this oligomer
(27). Comparison of the liganded homodimer structure with the
tetramer structure also suggests a reason for the observed
ligand-dependent dissociation of tetramers to dimer pairs.
Each of the constituent LBDs of the tetramer adopts the typical
apo-receptor conformation, in which H12 protrudes from the
body of the LBD but then, instead of protruding away from the
receptor, actually docks into the H3-H5 hydrophobic cleft re-
gion in the adjacent dimer utilizing its LMEML sequence that
resembles the coactivator LXXLL motif (21). Since ligand re-
positions H12, addition of ligand to tetramers would be ex-
pected to remove this part of the interdimer interface and
destabilize the tetramer.
While each of these crystal structures has provided major
insights into receptor function, it will be necessary to under-
stand the relationships between distinct receptor domains to
completely understand how nuclear receptors work. For exam-
ple, it is not clear why the RXR dimer binds DR-1 elements
with higher affinity than the tetramer. The structures of any
nuclear receptor containing multiple domains have not yet
been solved. In this study, we report the structural organiza-
tion of a hRXR protein containing the linked DBD and LBD
(hRXRAB) as revealed by solution synchrotron x-ray scat-
tering studies. We used the available crystallographic struc-
tures of the isolated hRXR DBD and LBD domains to place
them inside low resolution ab initio small-angle x-ray scatter-
ing (SAXS) models, which allowed us to assemble models of
both a dimer and a tetramer of hRXRAB. The results show
that the dimer is a U-shaped molecule with the two DBDs in
close proximity (2 nM) forming the tips of the U and separated
by an angle of 10°. By contrast, the tetramer is a more elon-
gated X-shaped molecule formed by two dimers in head to head
arrangement in which the DBDs are extended from the struc-
ture and further apart (6 nm) than in the dimer configuration
and are separated by an angle of 30°. These solution struc-
tures represent the first x-ray structural studies of nuclear
receptors that contain more than one domain and may explain
why RXR dimers recognize target genes with higher affinity
than tetramers.
MATERIALS AND METHODS
Protein Expression and Purification—The hRXRAB construct en-
compassing amino acid residues 126–462 was overexpressed in Esch-
erichia coli cells from strain BL21(DE3) harboring a pET28a() plas-
mid (Novagen). A Luria broth (LB) starter culture was inoculated with
a single colony of a LB-agar culture and grown overnight at 37 °C. The
initial culture was inoculated at 1% in a 2 YT culture (1.6% tryptone,
1% yeast extract, 0.5% NaCl w/v) and grown at 37 °C in 50 g/ml
kanamycin medium until A600 nm reached 0.8. Then 5 M of zinc sulfate
and 0.5 mM isopropyl-1-thio--D-galactopyranoside was added, and the
culture was allowed to grow for 2 h of incubation at 37 °C. After this
cells were harvested by centrifugation, and the pellets were resus-
pended in 10 ml/liter culture of buffer A (50 mM sodium phosphate, pH
7.5, 100 mM NaCl, 10% glycerol, 2 mM 2-mercaptoethanol, and 10 mM
imidazole). Phenylmethylsulfonyl fluoride and lysozyme were added to
1 mM and 220 g/ml, respectively, and the culture was placed on ice for
30 min. The lysate was sonicated for six times in 1-min intervals (power
40, Branson Sonifier 450), keeping the culture on ice, and then clarified
by centrifugation for 1 h at 20,000 rpm in a Sorval SS34 rotor. The
supernatant was loaded onto a 1.5-ml (per liter culture) Talon Super-
flow Metal Affinity Resin (Clontech) packed in a c10/10 column (Amer-
sham Biosciences) and equilibrated in buffer A (flow rate 70 cm/h). The
column was washed with buffer A, until the A280 nm of the eluent
returned to baseline, and then subsequently with buffer B (50 mM
sodium phosphate, pH 7.5, 300 mM NaCl, 10% glycerol, 2 mM 2-mer-
captoethanol, and 10 mM imidazole). Then, buffer A was applied until
the conductivity returned to that expected for the buffer A. The protein
was eluted with buffer C (50 mM sodium phosphate, pH 7.5, 100 mM
NaCl, 10% glycerol, 2 mM 2-mercaptoethanol, and 300 mM imidazole).
Fractions containing hRXRAB were pooled, diluted 1:1 with a buffer
of 10 mM Tris-HCl, pH 7.5, 10% glycerol, 5 mM DTT (dithiothreitol), and
0.5 mM EDTA. The fractions were then loaded onto Q-Sepharose High
Performance Resin (7 ml, Amersham Biosciences) and packed in a
c10/10 column (Amersham Biosciences) (1  10 cm, flow rate 70 cm/h)
that had been pre-equilibrated with this same buffer (plus 50 mM
NaCl). The column was then washed with 10 ml of a buffer of 10
mM Tris-HCl, pH 7.5, 50 mM NaCl, 10% glycerol, 5 mM DTT, and 0.5 mM
EDTA to remove unbound protein and eluted with a gradient of 50–500
mM NaCl. The protein eluted in two peaks, and the fractions of each
peak were pooled and concentrated. Protein content and purity of all
chromatographic fractions were checked by Coomassie Blue-stained
SDS gels. Protein concentrations were determined in parallel using the
Bio-Rad dye assay and bovine serum albumin as standard.
Size Exclusion Chromatography and Dynamic Light Scattering Ex-
periments—The protein oligomerization state was assessed by size ex-
clusion chromatography and dynamic light scattering. Each of two
protein elution peaks was separately concentrated and loaded onto a
Superdex 200 size exclusion column (1  30 cm, Amersham Bio-
sciences). The column was pre-equilibrated with a buffer of 10 mM
Tris-HCl, pH 8.0, 200 mM NaCl, and 5 mM DTT at a flow rate of 0.5
ml/min and standardized with the molecular mass calibration kit
(Amersham Biosciences) using 100 l of protein standard samples of a
known Stokes radii (thyroglobulin, 8.5 nm; ferritin, 6.1 nm; catalase,
5.22 nm; aldolase, 4.81 nm; bovine serum albumin, 3.55 nm; ovalbumin,
3.05 nm; chymotrypsinogen, 2.09 nm, and ribonuclease A, 1.64 nm). The
different oligomeric forms of RXRAB receptor were analyzed under
the same conditions. The initial protein concentrations of 2.2, 5.6, and
12.3 mg/ml (peak 1) and 3, 8.2, and 11 mg/ml (peak 2) were studied.
Dynamic light scattering measurements were performed with a
DynaPro MS200 instrument (Protein Solutions) at 4 °C using a 12-l
cuvette. The protein samples were concentrated to 1.17 and 7 mg/ml
(separately peak 1 and peak 2) in 10 mM Tris-HCl, pH 8.0, 200 mM
NaCl, 10% glycerol, and 5 mM DTT prior to measurements.
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Small-angle X-ray Scattering Measurements and Data Analysis—
SAXS data were collected at the small-angle scattering beamline on the
LNLS (National Synchrotron Light Laboratory, Campinas, Brazil) us-
ing one-dimensional position-sensitive detector (28). hRXR at the con-
centrations 2, 3.1, 6.3, and 14 mg/ml was measured at a wavelength 
0.138 nm for sample-detector distances of 632.5 and 1345.2 mm cover-
ing the momentum transfer range 0.1  q  6 nm1 (q  4sin/,
where 2 is the scattering angle). The scattering curves of the protein
solutions and the corresponding solvents were collected in a number of
short 30-s to 1-min frames to monitor radiation damage and beam
stability. The data were normalized to the intensity of the incident
beam and corrected for detector response.
The scattering of the buffer was subtracted, and the difference curves
were scaled for concentration. The distance distribution functions p(r)
and the radii of gyration Rg were evaluated by the indirect Fourier
transform program GNOM (29). The molecular masses of the oligomers
of hRXR in solution were estimated by comparison of the extrapolated
forward scattering I(0) with that of a reference solution of bovine serum
albumin with a known molecular mass of 66 kDa. Prior to the shape
analysis, a constant was subtracted from the experimental data to
ensure that the intensity at higher angles decays as q4 following
Porod’s law for the homogeneous particles (30). The value of the con-
stant is derived automatically from the outer part of the curve by linear
fitting in coordinates q4I(0) versus q4 by the shape determination pro-
gram DAMMIN (31). This procedure reduces the contribution from
scattering due to the internal protein structure and yields an approxi-
mation of the “shape scattering” curve (i.e. scattering from the excluded
volume of particle filled by constant density).
The experimental pair distribution functions do not contain any
negative part, which is an indication of the absence of interference
effects in the scattering curves produced by spatial correlations. This
argues that all solutions were sufficiently dilute to remove interference
effects. The structure function that describes interparticle correlations
may be equal to unity even at high concentrations for proteins of very
anisotropic shape (32).
Shape Determination—Low resolution particle shapes were restored
from the experimental SAXS data using two ab initio procedures. In the
first procedure (33, 34), the shape is represented by an angular envelope
function, parameterized in terms of spherical harmonics using multi-
pole expansion methods (35). The maximum number of the spherical
harmonics L is selected to keep the number of free parameters M 
(L  1)  6 close to the number of Shannon channels Ns  Dmaxqmax/
in the experimental data (36).
The computed scattering intensity of the envelope is compared with
the experimentally obtained one. The envelope is modified by minimiz-
ing the discrepancy  between the calculated and the experimental data
(36, 37). The discrepancy  is defined in Equation 1,







where N is a number of the experimental points and Iexp(qj) is the
experimental intensity and (qj) is its standard deviation in the
jth point.
The shapes of the hRXR dimers and tetramers were also restored
from the experimental data using another ab initio method as imple-
mented in DAMMIN (31). A sphere of diameter Dmax was filled by a
regular grid of points corresponding to a dense hexagonal packing of
small spheres (dummy atoms) of radius r0  Dmax. The structure of the
dummy atom model (DAM) is defined by a configuration X, assigning an
index to each atom corresponding to solvent (0) or solute particle (1).
The method searches for a compact interconnected configuration X,
minimizing the goal function in Equation 2,
fX		 2  PX	 (Eq. 2)
where  
 0 is the weight of the looseness penalty (31). Starting from
the initial spherical configuration, simulated annealing is employed for
the minimization (31).
Both models assume that the protein structure in solution can be
described by a constant electron density over its whole volume. How-
ever, short range fluctuations in electronic density that exist inside the
proteins actually yield a constant contribution at small q. To apply
SASHA and DAMMIN this constant contribution should be previously
subtracted from the experimental scattering curves. The assumption of
a two-electron density model (corresponding to the protein and the
solvent) is progressively weaker for increasing q outside the range
covered in the present measurements.
The coordinate sets for both hRXR LBD and DBD domains were
obtained from Protein Data Bank (PDB accession numbers 1G1U and
2NLL) (16, 19). Relative positions of the LBD and DBD domains were
found by iterative rotation of their envelope functions to minimize the
discrepancy with the ab initio low resolution structure using an auto-
mated procedure. The models were displayed using the program
MASSHA (38). Radii of gyration (Rg), maximum intraparticle distances
(Dmax), envelop functions, and scattering curves, were calculated from
these atomic coordinates with use of the program CRYSOL taking into
account the influence of the hydration shell (39). SUPCOMB (40) was
used to superimpose ab initio low resolution models with crystallo-
graphic structures.
RESULTS
SAXS Measurements of hRXR DBD-LBD Dimers and Tet-
ramers—The bacterially expressed hRXRAB preparation
eluted from the Q-Sepharose high performance resin ion ex-
change column in two peaks (1 and 2; see “Material and Meth-
ods”). The protein of both chromatographic fractions migrated
on SDS-polyacrylamide gels at a molecular weight that is con-
sistent with hRXRAB region at high purity (
95%; “Mate-
rial and Methods”). Thus, our preparation of hRXRAB exists
in two distinct forms. To assess the structural organization of
the hRXRAB in solution, separate synchrotron SAXS meas-
urements were performed on each peak. Experimental scatter-
ing curves from hRXR are presented in Fig. 1, and the struc-
tural parameters derived from these curves are given in
Table I.
The hRXRAB oligomers eluted in peaks 1 and 2 corre-
spond to molecular masses of 79 and 185 kDa, respectively, as
determined in SAXS experiments by comparison with a refer-
ence solution of bovine serum albumin (Table I). This suggests
that peaks 1 and 2 are composed respectively of hRXRAB
dimers and tetramers. Further support for this finding comes
from the size exclusion chromatography analysis (Fig. 2). Peak
1 protein Stokes radius was equal to 4.48 and 4.66 nm at
protein concentrations of 5.6 and 12.3 mg/ml, respectively.
Peak 2 protein Stokes radius varied from 5.2 to 5.7 nm at
several protein concentrations between 3 and 11 mg/ml. Dy-
namic light scattering experiments conducted on peak 1 and
peak 2 fractions at the concentrations 1.2 and 7 mg/ml gave,
respectively, experimental Stokes radii of 4.42 and 4.3 nm for
peak 1 and 5.13 and 5.42 nm for peak 2. These results are both
consistent with the idea that peaks 1 and 2 represent dimer
and tetramer, respectively. Determinations of Stokes radius
from size exclusion chromatography and dynamic light scatter-
ing agree with Stokes radii calculated from proposed low res-
olution SAXS models of the hRXRAB dimer and tetramer
(see below), which are 4.15 nm for dimer and 5.6 nm for tet-
ramer (41).
Concentration of the protein from peak 1 from 3 to 14 mg/ml
yielded SAXS curves that were virtually identical to the SAXS
data of the protein from the elution peak 2 at similar concen-
tration (data not shown). This suggests that the hRXRAB
dimer population in peak 1 can be converted to a tetramer
population at high protein concentration and is consistent with
the previous idea that the DBD-LBD dimer and tetramer pop-
ulations are in dynamic equilibrium that is influenced by pro-
tein concentration (14, 15).
The experimental values of Dmax and Rg, 19 and 5.27 nm for
the tetramer and 11.5 and 3.38 nm for the dimer, respectively,
suggest that the protein in both peaks is rather elongated
(Table I). The profiles of the distance distribution function p(r)
in Fig. 3 are typical for elongated particles (42). Nevertheless,
the Dmax of the tetramer (19 nm) is 7.5 nm larger than the
dimer (11.5 nm), which indicates that the tetramer is more
elongated than the dimer.
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Ab Initio Shape Determination Using Envelope Functions
(SASHA)—Shape determinations of the hRXR dimer and the
hRXR tetramer were performed using multipole expansion
methods. The experimental data were fitted ab initio by the
scattering from an envelope function starting from a spheri-
cal initial approximation (33, 34). The envelopes were repre-
sented with spherical harmonics up to L  4 (13 independent
parameters) and L  10 (31 independent parameters) for
dimer and tetramer, respectively. This was justified by the
fact that the portions of the scattering curves used for ab
initio shape determination using the envelope functions con-
tained Ns  6.7 Shannon channels for hRXR dimer and
Ns  14.1 Shannon channels for hRXR tetramer. The P2
symmetry was imposed in the case of dimer and P222 in the
case of tetramer.
The restored envelope for the dimer is displayed in Fig. 4,
and the fits to experimental data presented in Fig. 1. The
crystallographic models of hRXR LBD homodimer and two
FIG. 1. Experimental solution scattering curves of hRXRAB and results of the fitting procedures. a, dimer. b, hRXRAB tetramer.
Above, log I versus q focusing on the fitting of the experimental curve at high q. Below, details of the same curve at small q in linear scale with
an inset containing the correspondent Guinier plots (log I versus q2). (1), experimental curve; (2) experimental curve after subtraction of a constant
value as described under “Materials and Methods”; (3) scattering intensity from the DAMs (DAMMIN); (4) scattering intensity from the envelope
model (SASHA).
TABLE I
Structural parameters derived from SAXS data
Parameter/Sample
hRXR  dimer hRXR  tetramer
Exp.a Env.b DAMc Exp. Env. DAM
Mass (kDa) 79 (5) 185 (10)
Dmax (nm) 11.5 (5) 12.0 11.0 (2) 19 (1) 20 18 (2)
Rg (nm) 3.38 (5) 3.41 3.36 (1) 5.27 (4) 5.27 5.2 (2)
V (nm3) 105 151 119 (5)d 246 338 285 (3)
Free parameters 6.7e 13d 2718 14.1e 31f 3884
Discrepancy  0.57 1.32 (1) 0.99 1.30 (2)
Resolution (nm) 3.0 3.3 3.0 1.05 2 2.1
a Exp., calculated from the experimental data.
b Env., parameters of the envelope models.
c DAM, parameters of the dummy atoms models averaged over 10 models.
d Symmetry P2 imposed.
e Number of Shannon channels is given.
f Symmetry P222 imposed.
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hRXR DBD fragments could be unambiguously positioned
inside the envelope for the hRXR dimer. The restored enve-
lope for the tetramer is displayed in Fig. 5, and fits to the
experimental data are displayed in Fig. 1. By contrast to the
dimer, one hRXR LBD tetramer and four hRXR DBD frag-
ments fit an envelope for the hRXR tetramer. Two models of
the hRXR LBD dimers obtained by superposition of the crys-
tallographic structures with ab initio hRXR dimer structure
were placed within the tetramer ab initio models allowing for
their relative rotation and translation around common 2-fold
axis and adjustment of a relative orientation of the DBDs. This
superposition fits the ab initio retrieved low resolution tet-
ramer structure. Stokes radii calculated on the basis of re-
trieved low resolution structures of dimer and tetramer is
equal to 4.15 and 5.6 nm, respectively (41). These values agree
with experimental values observed for dimer and tetramer
populations in size exclusion chromatography and dynamic
light scattering.
Ab Initio Shape Determination Using DAM Technique (DAM-
MIN)—The particle shapes were also computed by the second
ab initio procedure using the DAMMIN program (31). In this
method, a sphere of diameter Dmax is filled with densely packed
small spheres (dummy atoms) with radius r0  Dmax. The
method searches to minimize differences between experimen-
tally determined scattering curves and those calculated from
DAM models using simulated annealing algorithm. The “loose-
ness” penalty term ensures that the procedure yields a compact
and interconnected model. The models were derived from the
experimental data assuming a 2-fold symmetry for the dimer
and p222 symmetry for the tetramer. The symmetry restric-
tions resulted in a significant reduction in the number of free
parameters of the models. The search volume for hRXR
dimer has been filled with NDAM  2718 dummy atoms with
a packing radius ra  0.375 nm within a sphere with the
diameter Dmax  11.5 nm. The search volumes for hRXR
tetramer have been filled with NDAM  3884 dummy atoms
with a packing radius ra  0.575 nm within a sphere with the
diameter Dmax  20.0 nm. Forty independent ab initio simu-
lations were performed. Of those, 395  10 dummy atoms were
attributed to the final model of hRXR dimer, and 265  5
atoms were assigned to the final model of the hRXR tetramer.
The obtained DAMs are presented in Figs. 4 and 5. DAM-
derived structure parameters also agree with the experimental
values (Table I). To verify the uniqueness of the shape resto-
ration using DAM, several independent restorations were per-
formed using different starting conditions yielding reproduci-
ble results. Maximum concentrations of the protein used for
SAXS solution studies of the hRXR dimer (3.1 mg/ml) and the
hRXR tetramer (14 mg/ml) limited the maximum resolution of
the final models to 3.0 and 2.1 nm, respectively (Table I). These
resolutions do not permit unambiguous determination of the
spatial positions of their secondary structure elements, but
allowed us to obtain the overall shape of the molecules and
relative position of their individual domains
hRXR Dimer and Tetramer Solution Structure—The best
fitting SAXS hRXRAB dimer model, constructed as de-
scribed in the preceding two sections, is shown in Fig. 4. The
dimer is an anisometric U-like-shaped molecule with two
clearly developed substructures that correspond to ho-
modimers of the LBD and DBD. The two LBDs form the plate-
like base of the U, and each LBD is connected by a long
-helical peptide, protruding like an arm, to its DBDs placed at
the extreme of the U (Fig. 4). The LBDs dimerize through the
interface described in the hRXR crystal structure (19, 20),
involving contacts between H9 and H10. The two long -helices
connecting LBDs to DBDs are slightly twisted around the
2-fold symmetry axis of the molecule. The DBDs form an angle
of 10 degrees in and out of plane of the LBDs but adopt a
position that is relatively close together in a head to head
orientation. The distance between the DBDs in solution is
slightly over 2 nm, which is comparable to the distance between
half-sites of a DR-1 element (3 nm). However, since these are
placed in a head to head orientation, rotation of one of the
DBDs by about 180° would be required for the homodimer to
bind to a DR-1 element. Assuming that this rotation could
occur, the data are consistent with the notion that the
FIG. 2. Representative size exclusion chromatograms of peak 1
and peak 2 protein fractions. RXRAB from Q-Sepharose peak 1
and peak 2 elution fractions at initial concentrations of 5.6 and 8.2
mg/ml, respectively, were loaded onto size exclusion Superdex HR200
10/30 column (Amersham Biosciences). Respective elution profiles are
shown as a dashed line (peak 1) and a solid line (peak 2). The value at
the top of each peak eluted from size exclusion column corresponds to
the elution volume of the RXRAB. The presence of the receptor in
these peaks was confirmed by SDS-electrophoresis (data not shown).
The elution volumes were used to calculate the Kav values (Kav 
(elution volume  column void volume)/(column total volume  column
void volume)). The value of 
 log Kav was used to determine the
Stokes radius for each peak from the column calibration plot (shown as
an inset). The column calibration plot was obtained eluting the protein
standards of known Stokes radii. Thyroglobulin, ferritin, catalase, al-
dolase, albumin, ovalbumin, chymotrypsinogen, and ribonuclease with
the correspondent Stokes radii of 8.5, 6.1, 5.22, 4.81, 3.55, 3.05, 2.09,
and 1.64 nm, respectively, were employed.
FIG. 3. Distance distribution functions of the hRXRAB
dimer and tetramer. Distance distribution functions of hRXRAB
dimer and tetramer are given in hollow circles and filled circles,
respectively.
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hRXRAB homodimer that we observe in solution is capable
of binding to its cognate DNA response element.
The hRXR tetramer is an oblate and more elongated X-
shaped molecule (Fig. 5 and Table I). Like the dimer, the
tetramer contains well developed substructures that corre-
spond to the LBDs and DBDs (Fig. 5). However, in the tet-
ramer, the LBDs comprise the center of the molecule and the
four DBDs protrude from the center. The relative position of
the LBDs is consistent with previous crystallographic and so-
lution studies of the hRXR LBDs, which show that the tet-
ramer is composed of a dimer of dimers where the LBDs of one
dimer are in head to head arrangement with the LBDs of the
other dimer. To fit better experimental scattering curves we
allowed for relative rotation of homodimers around their 2-fold
symmetry axis and for adjustment of the distance between
their centers of masses. The model is consistent with the idea
that individual dimer pairs utilize the previously defined in-
terface that overlaps the intersection of H9 and H10 and that
the extensive tetramerization interface utilizes interactions
between H3-H3, H11-H11, and H12 with the H3-H5 hydropho-
bic cleft region in the adjacent dimer (21), although limited
resolution of SAXS models does not allowed detailed descrip-
tion (Fig. 5). However, in striking contrast to the DBD-LBD
homodimers, the DBDs of the tetramer were not close together
(Figs. 4 and 5). Individual distances between the DBDs of each
dimer pair were 6 nm. This suggests that the DBDs of the RXR
tetramer would not be able to interact with the DR-1 element
without significant conformational changes. Thus, the x-ray
solution studies of the RXR tetramer present an explanation
why it may not bind well to DNA.
DISCUSSION
Small-angle x-ray scattering analyses yield data that per-
mits assembly of structural models of protein in solution. The
technique has some obvious disadvantages, especially relative
to x-ray crystallography. First, the data is collected at rela-
tively low resolution (nm range relative to angstrom range) and
therefore does not permit accurate determinations of the posi-
tion of individual amino acids and their side chains within the
structure. Second, the technique relies on modeling of rela-
tively low amounts of data and therefore depends upon as-
sumptions about the tertiary and quaternary structure of the
protein and internal symmetries of the overall structure (see
“Materials and Methods”). Should these assumptions prove
incorrect, then the deduced structures may prove to be inaccu-
rate. Nevertheless, the technique is useful for less detailed
descriptions of overall protein conformations and, further, can
be used in conjunction with published high resolution crystal
structures to infer the likely conformation of proteins in solu-
tion. In this sense, small-angle scattering may have some ad-
vantages over x-ray crystallography, which provides a high
resolution “snapshot” of a particular conformation within a
crystal lattice, which might be influenced by the crystal pack-
ing and can not always be readily interpreted in terms of the
oligomeric units of the protein in solution.
In this study, we reported low resolution synchrotron small-
angle scattering structures of unliganded hRXRAB oli-
gomers. We employed two independent ab initio shape resto-
ration methods to obtain a molecular envelope of RXR in its
dimeric and tetrameric forms to 3.0 and 2.1 nm, respectively.
The two ab initio shape restoration methods differ in that
FIG. 4. SAXS hRXRAB dimer en-
velopes derived from ab initio calcu-
lations. a, upper row shows a superposi-
tion of the envelop model computed by
SASHA (34) to the average of ten DAMs
obtained by DAMMIN (31), and the lower
row represent the superposition of the
same ten DAMs to the x-ray structure of
the hRXR LBD dimer (21) and two
hRXR DBDs (23). Grid space is 2 nm. b
and c are the same model rotated coun-
terclockwise by 90° around the z- and y-
axes, respectively.
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SASHA modeling yields an overall molecular envelope,
whereas DAMMIN modeling provides a dummy atoms model.
Figs. 4 and 5 demonstrate that the dummy atoms derived from
the DAMMIN model are highly dense inside the envelope de-
rived from the SASHA model, whereas density of dummy at-
oms outside it is low. Given the differences in the number of
adjustable parameters (Table I), the methods therefore agree
well within the limits imposed by the intrinsically low resolu-
tion of SAXS. Our models for dimer and tetramer forms indi-
cate that both oligomers are relatively elongated and further
suggest that the dimer adopts an oblate conformation, whereas
the tetramer adopts an X-shaped conformation. The Stokes
radii computed on the basis of the proposed low resolution
models for both oligomers agrees well with the experimental
measurements of Stokes radii independently obtained by size
exclusion chromatography and dynamic light scattering stud-
ies (see “Results”), providing independent biochemical verifica-
tion of our models.
In an attempt to understand the divergent nature of the
dimer and tetramer shapes, we positioned published crystallo-
graphic models of the hRXR DBD fragment (23) and hRXR
LBD homodimers/homotetramers (21) within the ab initio
dimer and tetramer structures. Internal P2 and P222 symme-
tries were imposed in the case of the dimer and the tetramer,
respectively (Figs. 4 and 5). These symmetries correspond to
the internal symmetry of the previously determined RXR
LBD crystal structure (21) and were also previously confirmed
by solution scattering studies of the same LBD protein (20).
Given these constraints, the crystallographic models show a
relatively good fit into the dimer and tetramer envelopes. The
likeliest hRXRAB dimer conformation is a U-shaped struc-
ture with the two DBDs occupying the tips of both arms of the
U. The DBDs are closely positioned in such a way that they
could contact DNA without major conformational changes of
the protein. However, as discussed in the Introduction, RXR
homodimers preferentially bind to DR-1 elements containing
DNA half-sites spaced as direct repeats. Thus, if the LBDs are
dimerized as shown in this structure and by mutational anal-
yses one of the DBDs would have to rotate by 170–180° for
the homodimer to bind to DNA. Alternatively, the DBD-LBD
conformation that is revealed in this structure could bind DNA
if one of the DBDs were to bind nonspecifically to one of the
half-sites. By contrast, the hRXRAB tetramer adopts an
X-shaped structure in solution. The LBDs are known to tet-
ramerize by forming a head to head arrangement of paired
dimers (dimer of dimers) with extensive contacts between H3-
H3, H11-H11, and H12 with the coactivator cleft of the neigh-
boring molecule. The likeliest tetramer structure fits the head
to head arrangement of LBD homodimers into the middle of the
X shape, and the DBDs would occupy the tips of the four points.
Interestingly, the DBDs of the tetramer would be widely spaced
in this configuration and therefore unlikely to bind DR-1 ele-
ments with high affinity without major conformational
changes. Thus, we propose that the dimeric and tetrameric
forms of the LBD differentially position the RXR DBDs, sug-
gesting that RXR tertiary structure is sensitive to alterations
in its quaternary state. These low resolution structures repre-
sent the first models proposed for a nuclear receptor containing
both a DBD and LBD. Moreover, our models suggest an expla-
nation for the observed inability of the unliganded tetramer to
bind to DNA.
Although these results cannot absolutely assure that other
FIG. 5. SAXS hRXRAB tetramer
models obtained by two independent
ab initio approaches. a, upper row
shows a superposition of the envelop
model obtained by SASHA (34) to the av-
erage of ten DAM calculated by DAMMIN
(31), and the lower row represents the
superposition of the same ten DAM to the
x-ray structure of the hRXR LBD tet-
ramer (21) and four hRXR DBDs (23).
Grid space is 2 nm. b and c are the same
model rotated counterclockwise by 90°
around the z- and y-axes, respectively.
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models would not give a better fit, we believe that the obtained
solutions must be close to reality. First, the molecular enve-
lopes obtained by two independent shape restoration methods
(SASHA and DAMMIN) give similar solutions and the deduced
Stokes radii from the models correspond well to the observed
Stokes radii. Second, the DBD and LBD crystal structures fit
well into the overall molecular envelopes. Third, the maximum
dimensions retrieved from the p(r) function impose rather elon-
gated shapes that are hard to explain by alternative place-
ments of RXR LBDs and DBDs without invoking conformations
that contradict previous results from high resolution crystal-
lography and molecular genetics. Nevertheless, while the ma-
jority of dummy atoms derived from the DAMMIN modeling
technique fit into the molecular envelope derived from the
SASHA modeling technique, we recognize that there are dis-
crepancies in the placement of some DAMs (Figs. 4a and 5a).
These differences could reflect a natural level of error in mod-
eling techniques or uncertainties in the structure of the mole-
cule in solution at these locations. We can not distinguish these
possibilities, but it is interesting that the greatest disagree-
ments in the dimer structure lie around the upper part of the
LBD around the predicted position of H12 and the greatest
disagreements in the tetramer structure lie close to the pre-
dicted position of the DBDs. It is intriguing to suggest that
these discrepancies between techniques may reflect relative
mobility of these regions of the protein in solution.
While solution x-ray studies can tell us that the relative
orientation of the LBD and DBD may differ in the dimer and
tetramer forms, the relatively low resolution of the structures
prevents us from learning why. We suggest that differences in
the conformation of the LBDs in the dimer and tetramer form
alter the relative position of the H1/hinge region and reposition
the DBDs. However, these subtle changes, if they exist, would
be too small to be perceived in solution x-ray scattering. None-
theless, we note that several distinct lines of evidence indicate
that nuclear receptor LBDs must be able to influence the be-
havior of the DBD. For instance, RXR homodimer binding to
DR-1 elements is enhanced by hormone. Thus, ligand-induced
conformational changes in the LBD must improve the fit be-
tween hRXR and DR-1 and increase the affinity of the interac-
tion. Likewise, TR homodimer binding to DR-4 and to an in-
verted palindromic element (F2) is reduced by hormone
(43–45). In the case of TR homodimers, we hypothesize that
ligand-induced conformational changes alter the relative posi-
tion of the TR DBDs and thus reduce the fit of the TR for both
types of response element. It will be important to obtain crystal
structures of liganded nuclear receptors containing more than
one domain and bound to a variety of DNA elements to under-
stand these phenomena.
The dynamic equilibrium between RXR oligomers is influ-
enced by receptor concentrations, ligand, and DNA (14, 15).
Thus, it seems plausible that sequestration of RXR in tetra-
mers in vivo could provide a mechanism for the cell to store an
excess of receptors until physiological functions related to RXR
homodimer and heterodimer activities are called into action
(14, 15). In addition to the inactivation revealed by the current
studies through separation of the RXR DBDs, a second mech-
anism for inactivation is provided by structural studies of the
RXR LBD tetramer (21). In this case, H12 of one receptor binds
to the H3-H5 region of the neighboring molecule, an interaction
that is partially analogous to the way that coactivator peptides
bind to the nuclear receptor hydrophobic cleft. Placement of
H12 from one receptor into the H3-H5 region of the other
receptor prevents coactivator binding by occluding the hydro-
phobic cleft. Our recent studies revealed that the TR and RXR
hydrophobic cleft also binds the corepressor N-CoR, suggesting
that the orientation of H12 in the tetramer could also occlude
the RXR N-CoR interaction surface (46).
While our studies have uncovered possible structures of the
unliganded hRXRAB tetramer, RXR may also be able to
form biologically active tetramers in a different configuration.
The cellular retinol-binding protein II (CRBPII) promoter con-
tains two non-optimal DR-1 sites that are poorly recognized by
the RXR dimer, suggesting that the RXR tetramer is the active
species for controlling expression of CRBPII (47–49). These
data argue that RXR tetramers control gene regulation in vivo
through cooperative DNA binding to the CRBPII promoter (47)
and to a wide variety of four differently oriented half-sites both
in vitro and in vivo (49). While the interactive surfaces leading
to the formation of this type of tetramer are also located in the
LBD (49), it is likely that this tetramer is different from the one
that we have described here because hormone-dependent acti-
vation of CRBPII gene expression will require coactivator re-
cruitment, which as discussed above would be excluded in
the tetramer structure that was used to obtain the model in the
current studies. We also stress that our studies exclude the
RXR N-terminal domain. RXR or RXR, but not RXR, can
form tetramers cooperatively on the CRBP-II promoter and
regulate this gene efficiently (49), and the differences between
the isoforms maps to the RXR N-terminal domain. This sug-
gests the RXR N-terminal domain may play an important role
in regulating formation of the active DNA and ligand-depend-
ent tetramer.
In conclusion, the low resolution solution structures for the
hRXRAB region determined in this work provides the first
three-dimensional model for the member of the nuclear recep-
tor super family containing more then one functional domain.
Our studies suggest a possible explanation for the previously
observed differences in DNA binding activity between dimers
and tetramers. The present ab initio models of hRXR dimer
and hRXR tetramer also provide a basis for further analysis
of the hRXR interaction with ligands and DNA response
elements.
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